
Mazdutide Peptide Therapy
Benefits, Side Effects, Cost & Protocols
Mazdutide is a dual GLP-1/glucagon receptor agonist developed by Innovent Biologics for the treatment of obesity and type 2 diabetes. It combines GLP-1-mediated appetite suppression with glucagon-mediated energy expenditure increases.
Clinically Reviewed
Reviewed by Alex Evans, PharmD, MBA · Updated May 2026
Evidence-Based
Sourced from FDA, PubMed & ClinicalTrials.gov · View sources
Who Is Mazdutide Best For?
How Mazdutide Works
Dual GLP-1 and glucagon receptor agonist that may enhance metabolic effects through complementary pathways.
Mazdutide FAQ
What is MAZDUTIDE?
Mazdutide is an emerging dual agonist peptide targeting both GLP-1 and glucagon receptors, representing the next generation of weight management research compounds.
How does MAZDUTIDE work?
Dual GLP-1 and glucagon receptor agonist that may enhance metabolic effects through complementary pathways.
Is MAZDUTIDE legal to buy?
MAZDUTIDE is sold as a research chemical for laboratory use only. It is not approved for human use by the FDA. Regulations vary by jurisdiction.
Where can I buy MAZDUTIDE?
MAZDUTIDE is available as a research compound from verified online vendors. Always verify third-party testing before purchasing.
What category does MAZDUTIDE belong to?
MAZDUTIDE is primarily classified as a weight loss & metabolic peptide. Peptides researched for their effects on weight management, fat metabolism, appetite regulation, and metabolic enhancement. This category includes GLP-1 agonists, dual/triple agonists, and other metabolic peptides.
What are the research benefits of MAZDUTIDE?
MAZDUTIDE has been studied for: Weight management research, Dual mechanism, Metabolic enhancement. New dual agonist; emerging weight loss research peptide.
Key Studies
39 total on PubMed29 human trialsMazdutide versus dulaglutide in Chinese adults with type 2 diabetes
Guo L, Zhang B, Xue X et al
NaturePhase 3
Mazdutide superior to dulaglutide for HbA1c reduction and weight loss in Chinese adults with type 2 diabetes.
Mazdutide superior to dulaglutide for HbA1c reduction and weight loss in Chinese adults with type 2 diabetes
Once-Weekly Mazdutide in Chinese Adults with Obesity or Overweight
Ji L, Jiang H, Bi Y et al
N Engl J MedPhase 3
Mazdutide 4-6 mg reduced body weight by 11-14% at 48 weeks vs 0.3% with placebo.
Mazdutide 4-6 mg reduced body weight by 11-14% at 48 weeks vs 0.3% with placebo
Mazdutide versus Semaglutide for the treatment of type 2 diabetes and obesity: Rationale, design and baseline data of DREAMS-3 phase 3 trial
Luo Y, Jiang H, Shi B et al
Contemp Clin Trials · Contemp Clin TrialsPhase 3
Mazdutide vs semaglutide efficacy and safety in Chinese adults with type 2 diabetes and obesity.
Mazdutide vs semaglutide efficacy and safety in Chinese adults with type 2 diabetes and obesity
Mazdutide versus placebo in Chinese adults with type 2 diabetes
Mazdutide Compound Data
Mazdutide News
Mazdutide vs. Tirzepatide: Which Is Better for Weight Control? - Ro
Ro · 18 days ago
Once-Weekly Mazdutide in Chinese Adults with Obesity or Overweight - The New England Journal of Medicine
The New England Journal of Medicine · 10 months ago
Mazdutide versus dulaglutide in Chinese adults with type 2 diabetes - Nature
Nature · 5 months ago
Mazdutide Outperforms Dulaglutide in Type 2 Diabetes Trial - EMJ
EMJ · 4 months ago
Innovent Announces Mazdutide, First Dual GCG/GLP-1 Receptor Agonist, Received Approval from China's NMPA for Chronic Weight Management - PR Newswire
PR Newswire · 10 months ago
News aggregated via Google News. Inclusion does not imply endorsement.
Ready to explore Mazdutide with a provider?
Take our 2-minute quiz to get matched with a board-certified provider specializing in Mazdutide.
Take the Quiz →